Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-BCMA-CAR-transduced T cells (Southwest Hospital)
- Development stage
- Unknown
- Lead developer
- Southwest Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Southwest Hospital in China. It targets the B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), which is preferentially expressed on mature B lymphocytes and malignant plasma cells. The therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes BCMA, enabling the immune system to specifically identify and eliminate malignant B cells. It is primarily being evaluated as a treatment for relapsed or refractory B-cell malignancies, including multiple myeloma, B-cell leukemia, and B-cell lymphoma, and is specifically investigated as a potential rescue therapy for patients who have relapsed after CD19-targeted CAR-T treatments.
- Other names
- BCMA-targeted CAR-T cellsAnti-BCMA-CAR-TAnti-BCMA-CAR-transduced T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on Anti-BCMA-CAR-transduced T cells (Southwest Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-BCMA-CAR-transduced T cells (Southwest Hospital).